Nektar Therapeutics Inc. NKTR on Thursday shared new data from its ongoing REZOLVE-AD Phase 2b study of rezpegaldesleukin, an IL-2 pathway agonist and regulatory T-cell (Treg) proliferator, at the 2025 European Academy of Dermatology and Venereology Congress.The study showed that rezpegaldesleukin met the primary endpoint, with statistically significant improvement in the Eczema Area and Severity Index (EASI) at week 16 compared with placebo. Key secondary endpoints—including EASI-75, EASI-90, Itch Numerica ...